Model-based drug discovery: implementation and impact.

Model-based drug discovery (MBDDx) aims to build and continuously improve the quantitative understanding of the relation between drug exposure (target engagement) efficacy and safety, to support target validation; to define compound property criteria for lead optimization and safety margins; to set the starting dose; and to predict human dose and scheduling for clinical candidates alone, or in combination with other medicines. AstraZeneca has systematically implemented MBDDx within all drug discovery programs, with a focused investment to build a preclinical modeling and simulation capability and an in vivo information platform and architecture, the implementation, impact and learning of which are discussed here.

[1]  William J Jusko,et al.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.

[2]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[3]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[4]  Hugues Dolgos,et al.  Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.

[5]  Vikram Sinha,et al.  Model-Based Drug Development: The Road to Quantitative Pharmacology , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[7]  P. H. van der Graaf,et al.  Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development. , 2012, Bioanalysis.

[8]  J. Arrowsmith.  Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[9]  P. Lowe,et al.  From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics , 2011, The AAPS Journal.

[10]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.

[11]  J. Arrowsmith.  Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[12]  R. Sarangapani,et al.  On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  S. Visser,et al.  Correct assessment of new compounds using in vivo screening models can reduce false positives. , 2009, Drug discovery today.

[14]  C. Peck.  Quantitative clinical pharmacology is transforming drug regulation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[16]  Johan Gabrielsson,et al.  Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.

[17]  Marc Pfister,et al.  Model‐Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development , 2010, Journal of clinical pharmacology.

[18]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[19]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[20]  Jing Li,et al.  Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background , 2012, Molecular Cancer Therapeutics.

[21]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[22]  Ralf Herold,et al.  Pharmacometrics for Regulatory Decision Making , 2011, Clinical pharmacokinetics.

[23]  Richard W Peck.  Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. , 2007, Drug discovery today.

[24]  Steven W. Martin,et al.  The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.

[25]  M. Danhof,et al.  Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development , 2013, CPT: pharmacometrics & systems pharmacology.

[26]  Marc Pfister,et al.  Fostering Culture and Optimizing Organizational Structure for Implementing Model‐Based Drug Development , 2010, Journal of clinical pharmacology.

[27]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[28]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[29]  P. Lund,et al.  In Vivo and Ex Vivo Inhibition of Spinal Nerve Ligation-Induced Ectopic Activity by Sodium Channel Blockers Correlate to In Vitro Inhibition of NaV1.7 and Clinical Efficacy: A Pharmacokinetic-Pharmacodynamic Translational Approach , 2013, Pharmaceutical Research.

[30]  M. Danhof,et al.  5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization , 2007 .

[31]  Marc Pfister,et al.  Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry , 2010, Journal of clinical pharmacology.

[32]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[33]  S. Visser,et al.  Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data , 2013, European Journal of Clinical Pharmacology.

[34]  Johan Gabrielsson,et al.  Optimising in vivo pharmacology studies--Practical PKPD considerations. , 2010, Journal of pharmacological and toxicological methods.

[35]  J. Gabrielsson,et al.  Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology , 2009, Journal of Pharmacology and Experimental Therapeutics.

[36]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[37]  O. Bjerrum,et al.  Effective Integration of Systems Biology, Biomarkers, Biosimulation, and Modeling in Streamlining Drug Development , 2007, Journal of clinical pharmacology.

[38]  Michael Rowley,et al.  Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.

[39]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[40]  M. Karlsson,et al.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.